Clinical trial
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study
NCT07908147 is registered in ClinicalTrials.gov with Olivia Newton-John Cancer Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- March 31, 2027
- Completion date
- March 31, 2028
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
glioblastoma (gbm), idh wildtype glioblastoma
Arms
As registered; 3 arms.
-
BRAF-altered
Plixorafenib 900 mg orally once daily continuously
-
NTRK fusion-positive
Larotrectinib 100 mg orally twice daily continuously
-
Mismatch repair deficient
Cadonilimab 6 mg/kg intravenously on Days 1 and 15
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Feasibility of Rapid Molecular Profiling and Matched Targeted Therapy
To assess the feasibility of performing rapid molecular profiling before chemoradiation and initiating matched targeted therapy in patients with actionable molecular alterations.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Larotrectinib
- US 11337967; expires May 16, 2037; assignee BOW RIVER LLC
- US 11974998; expires May 16, 2037; assignee BOW RIVER LLC
- US 10045991; expires April 4, 2037; assignee Loxo Oncology, Inc.
- US 10137127; expires April 4, 2037; assignee Loxo Oncology, Inc.
- US 10668072; expires April 4, 2037; assignee Loxo Oncology, Inc.
- +15 more patents
Lead sponsor's other trials
Olivia Newton-John Cancer Research Institute, most recent start first.
+8 more trials See the organization page
Similar trials
Same condition (Glioblastoma) and phase, most recent start first.
+619 more trials See the condition page